Inhibitory Control Deficits Associated with Upregulation of CB₁R in the HIV-1 Tat Transgenic Mouse Model of Hand

Ian R. Jacobs[1] · Changqing Xu[1] · Douglas J. Hermes[1] · Alexis F. League[1] · Callie Xu[1] · Bhupendra Nath[2] ·
Wei Jiang[3,4] · Micah J. Niphakis[5] · Benjamin F. Cravatt[5] · Ken Mackie[6] · Somnath Mukhopadhyay[2] ·
Aron H. Lichtman[7] · Bogna M. Ignatowska-Jankowska[8] · Sylvia Fitting[1]

Abstract

In the era of combined antiretroviral therapy, HIV-1 infected individuals are living longer lives; however, longevity is met with an increasing number of HIV-1 associated neurocognitive disorders (HAND) diagnoses. The transactivator of transcription (Tat) is known to mediate the neurotoxic effects in HAND by acting directly on neurons and also indirectly via its actions on glia. The Go/No-Go (GNG) task was used to examine HAND in the Tat transgenic mouse model. The GNG task involves subjects discriminating between two stimuli sets in order to determine whether or not to inhibit a previously trained response. Data reveal inhibitory control deficits in female Tat(+) mice ($p = .048$) and an upregulation of cannabinoid type 1 receptors (CB₁R) in the infralimbic (IL) cortex in the same female Tat(+) group ($p < .05$). A significant negative correlation was noted between inhibitory control and IL CB₁R expression ($r = −.543$, $p = .045$), with CB₁R expression predicting 30% of the variance of inhibitory control ($R^2 = .295$, $p = .045$). Furthermore, there was a significant increase in spontaneous excitatory postsynaptic current (sEPSC) frequencies in Tat(+) compared to Tat(−) mice ($p = .008$, across sexes). The increase in sEPSC frequency was significantly attenuated by bath application of PF3845, a fatty acid amide hydrolase (FAAH) enzyme inhibitor ($p < .001$). Overall, the GNG task is a viable measure to assess inhibitory control deficits in Tat transgenic mice and results suggest a potential therapeutic treatment for the observed deficits with drugs which modulate endocannabinoid enzyme activity.

✉ Ian R. Jacobs
jacobsir@email.unc.edu

✉ Sylvia Fitting
sfitting@email.unc.edu

1. Department of Psychology & Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

2. Department of Chemistry & Biochemistry, North Carolina Central University, Durham, NC 27707, USA

3. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA

4. Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA

5. The Skaggs Institute for Chemical Biology, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

6. Department of Psychological & Brain Sciences, Indiana University, Bloomington, IN 47405, USA

7. Department of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA

8. Neuronal Rhythms in Movement Unit, Okinawa Institute of Science and Technology, Okinawa 904-0495, Japan

Introduction

The World Health Organization estimates 36.7 million people are diagnosed with human immunodeficiency virus type 1 (HIV-1) worldwide, which has been considered a fatal diagnosis before antiretroviral treatments were established. With the advent of combined antiretroviral therapy (cART), HIV-1 infection has become a chronic but manageable condition with decreased mortality rates and increased life expectancies (Harrison et al. 2010). Before cART, the later stages in the progression of HIV-1 infection were marked with HIV-1 associated dementia (HAD), but a newer, milder form of cognitive impairment has emerged during the post-cART era called HIV-1-associated neurocognitive disorders (HAND) (Ellis et al. 2007). Symptoms that have been associated with HAND in the post-cART era include reduced mental acuity, and deficits in working memory, attention, and inhibitory control (Connolly et al. 2014; Ernst et al. 2003; Wang et al. 2017) that are specifically associated with cortical brain structures such as the prefrontal cortex (PFC) (Heaton et al. 2011).

It is unclear how HAND manifests and what molecular and cellular mechanisms are driving HAND, however the severity of synaptic disruption and dendritic injury is correlated with the severity of expressed symptoms of HAND (Everall et al. 1999; Masliah et al. 1997). As the virus itself does not directly infect neurons, neuronal damage and synaptodendritic injury occurs indirectly through the release of toxic substances from infected microglia and other non-neuronal cells in the central nervous system (CNS), including viral proteins, cytokines/chemokines, and free radicals. Among the viral proteins, the transactivator of transcription (Tat) in particular plays a key role in HAND pathogenesis as Tat continues to be detected in the HIV-1 infected brain despite cART (Johnson et al. 2013; Mediouni et al. 2012). Further, expression of the Tat protein in transgenic animal models, without the presence of the virus itself or other viral proteins, tend to mirror the neuropathology and cognitive deficits observed in HIV-1 patients with HAND (Bruce-Keller et al. 2008; Carey et al. 2012; Fitting et al. 2010; Hauser et al. 2009; Kesby et al. 2014; Kesby et al. 2015; Marks et al. 2016; Maung et al. 2014; Mediouni et al. 2015; Paris et al. 2014a; Paris et al. 2014c; Toggas et al. 1994). Tat exerts its effects via multiple mechanisms, including direct and indirect effects on neurons (Chen et al. 1997; Cheng et al. 1998; El-Hage et al. 2008; El-Hage et al. 2005; Kutsch et al. 2000; Lipton 1993; Liu et al. 2000; Magnuson et al. 1995; Nath 2002). Tat can depolarize neurons directly by interacting with a variety of surface receptors, such as NMDA receptors (Eugenin et al. 2007; Longordo et al. 2006; Raybuck et al. 2017), and potentiate glutamate-induced excitotoxicity (Longordo et al. 2006), leading to increases in $[Ca^{2+}]_i$, and dendritic structural and functional defects in neurons (Fitting et al. 2014; Green et al. 2018; Haughey et al. 1999; Mattson et al. 2005). Additionally, Tat

can induce neurotoxicity through indirect mechanisms via its actions on microglia and astrocytes by stimulating the production of proinflammatory cytokines (Chen et al. 1997), inducing TNF-α and IL-1 in monocytes and macrophages and a milieu of cytokines and chemokines in astrocytes, including IL-8, RANTES, MCP-1, and TNF-α (El-Hage et al. 2005; Kutsch et al. 2000).

One avenue for treating the effects of HIV-1 Tat in the brain is the modulation of the endocannabinoid (eCB) system. Modulating function of endogenous cannabinoids emerges as a promising therapeutic target in several neurodegenerative diseases due to their anti-excitotoxic and anti-inflammatory properties (Pertwee 2014; Scotter et al. 2010). Endocannabinoids have been reported to be up-regulated in disorders, such as Parkinson's disease and Alzheimer's disease, and reduce or abolish unwanted effects of these disorders or slow their progression (Pertwee 2014; Scotter et al. 2010). Interestingly, an upregulation of expression of cannabinoid type 1 and type 2 receptor levels (CB$_1$R and CB$_2$R, respectively) has been demonstrated in the CNS of HIV-1-infected individuals (Cosenza-Nashat et al. 2011) and in simian immunodeficiency virus (SIV) encephalitis (Benito et al. 2005). There is support for existing cannabinoid signaling pathways that can decrease neuronal injury, including CB$_1$R activation as well as inhibition of NMDAR-mediated calcium influx (Liu et al. 2009). Multiple studies have indicated that CB$_1$R stimulation limits synaptic excitation mediated by glutamate with CB$_1$R activation decreasing glutamate-mediated excitatory postsynaptic currents (EPSCs) (Andre et al. 2010; Chevaleyre et al. 2006; Harkany et al. 2008; Marsicano et al. 2003; Monory et al. 2006; Rossi et al. 2011). Nevertheless, therapeutic use of direct CB$_1$R agonists is limited due to the pervasive psychoactive side effects associated with CB$_1$R agonists that include sensorimotor, affective and cognitive disturbances (Di Marzo 2008). Thus, research efforts have focused on development of drugs targeting components of the endogenous cannabinoid system, including enzymes regulating the biosynthesis and degradation of the two major endogenous cannabinoids N-arachidonoylethanolamine (anandamide/AEA) and 2-arachidonoylglycerol (2-AG) (Ahn et al. 2008; Lichtman et al. 2010; Petrosino and Di Marzo 2010). There is strong preclinical evidence that selective inhibitors of the main AEA-metabolizing enzyme, fatty acid amide hydrolase (FAAH), can ameliorate the unwanted effects in a variety of different laboratory animal models of neurodegenerative diseases (Naidoo et al. 2011; Pertwee 2014). The new generation of hydrolytic enzyme inhibitors, such as the FAAH enzyme inhibitor PF3845, has demonstrated highly improved selectivity, potency and produce less side effects compared to previously available compounds (Ahn et al. 2009; Booker et al. 2012; Ignatowska-Jankowska et al. 2015; Ignatowska-Jankowska et al. 2014; Niphakis et al. 2013; Parker et al. 2015). In a recent in vitro study we have demonstrated that

PF3845 is protective against HIV-1 Tat-induced excitotoxicity and neuronal injury by involving CB_1R and CB_2R-mediated mechanisms (Hermes et al. 2018; Xu et al. 2017).

The aim of the present study was (1) to determine the effects of Tat on inhibitory control by using the PFC-related operant conditioning Go/No-Go (GNG) task, (2) to assess the effects of Tat on the eCB system by quantifying the changes in CB_1R expression in the medial PFC (mPFC) using immunohistochemistry, and (3) to investigate the potential neuroprotective effects of the FAAH enzyme inhibitor PF3845 on Tat-induced increases in glutamatergic neurotransmission ex vivo. Results revealed inhibitory control deficits in female Tat(+) mice that also demonstrated an upregulation of CB_1R expression in the infralimbic cortex (IL). A significant negative correlation between inhibitory control and IL CB_1R expression demonstrated that deficits in inhibitory control were associated with an upregulation of IL CB_1R expression, with IL CB_1R expression predicting 30% of the variance of inhibitory control. Further, Tat-induced increases in spontaneous excitatory postsynaptic current (sEPSC) frequencies (females and males) were attenuated by application of PF3845, indicating a potential role of the eCB system in the context of HAND.

Methods

Subjects

Doxycycline (DOX)-inducible, brain-specific HIV-1$_{IIIB}$ Tat$_{1-86}$ transgenic mice were developed on a C57BL/6J hybrid background as described in detail in previous literature (Bruce-Keller et al. 2008; Hahn et al. 2015b). Tat expression, which is under the control of a tetracycline-responsive promoter controlled by glial fibrillary acidic protein (GFAP) expression, was induced with a specially formulated chow containing 6 mg/g DOX (product TD.09282; Harlan, Indianapolis, IN). Inducible Tat(+) transgenic mice express both *GFAP-rtTA* and *TRE-tat* genes, while control Tat(−) transgenic mice express only the *GFAP-rtTA* genes. At ~4 weeks of age transgenic mice were genotyped to confirm the presence of Tat and/or *rtTA* transgenes.

In all experiments animals were counterbalanced for sex within groups. For the behavioral and immunohistochemistry studies, adult transgenic mice (8 weeks of age) were experimental naive and included 7 Tat(+) mice (4 female) and 7 Tat(−) mice (3 female). To induce the Tat protein animals were fed DOX at ~6 weeks of age and kept on this diet until sacrificed for immunohistochemistry experiments (more than 10 months of DOX treatment). For the western blot and electrophysiology studies a new set of adult Tat transgenic mice [Tat(−) and Tat(+), DOX exposure for more than 5 months and at least ~1 month, respectively] was used with at least 6–8

mice in each group (3–4 females/per group). All animals were bred by the University of North Carolina Division of Comparative Medicine (UNC DCM) and individually housed (starting at 6 weeks of age) under a 12/12 h light-dark (LD) cycle. The colony room temperature was maintained at 21 °C and 32% humidity. All animal procedures were approved by the University of North Carolina Institutional Animal Care and Use Committee (IACUC) and are in keeping with AAALAC guidelines.

Apparatus

Standard mouse experimental chambers (MED Associates ENV-307 W) were housed in sound and light attenuating cubicles (MED Associates ENV-022MD). Each chamber was equipped with a curved five nose-poke wall (MED Associates ENV-115C) where subjects performed their responses. Each nose-poke contained an imbedded yellow LED to illuminate the port. A 28 V DC, 100 mA house light (MED Associates ENV-215 W) was mounted on the wall opposite of the curved five nose-poke wall and illuminated the chamber during each session. Sucrose pellets (BioServ Product# F06233 - Dustless Precision Pellets®) weighing 20 mg served as reinforcers and were delivered via a pellet dispenser (MED Associates ENV-203-20) into a receptacle (MED Associates ENV-303 W), which was illuminated by a receptacle light (MED Associates ENV-303RL). The pellet receptacle was located under the house light, opposite of the curved nose-poke wall. Behavioral testing occurred in a dark room illuminated by red fluorescent lighting. The testing room was kept at 22 °C room temperature with 30% humidity.

Behavioral Training

Training took place over four phases adapted from procedures described in previous literature (Gubner et al. 2010; Loos et al. 2010): shaping the nose-poke response, shaping the go response, titrating the limited hold (LH), and testing. Unless otherwise stated, advancement from a phase was contingent on criteria requiring the subject to earn 40 reinforcers and maintain 80% accuracy on 2 consecutive days. Subjects advanced through the phases individually as they independently reached criteria. This advancement style ensured that all subjects received the same relative training and prevented overtraining. Additionally, the intertrial interval (ITI) used in all phases was 10 s. The house light was illuminated 1 s before the start of the trial and was terminated once the animal retrieved a reinforcer. All sessions terminated after 30 min or after 100 reinforcers were earned.

After individual housing placement, mice were allowed to acclimate to their new living conditions for one week and on the final two days, weights were taken and averaged to compute the initial weights from which the 85% target weight

could be derived. At ~7 weeks of age, mice were gradually transitioned from ad libitum feeding to a restricted diet to lower their body weights to 85% of initial. At ~8 weeks of age mice entered the study and underwent 3 training phases (please see supplemental material for full description of the 3 training phases). Briefly, phase 1 started with magazine training in which a pellet was dispensed on a variable-time 2 min schedule to train the animal where reinforcement was delivered and familiarized them with the sound of a pellet being dispensed. Once subjects met criteria for this phase, they advanced to phase 2 where subjects were introduced to the chain of behaviors necessary to receive reinforcement on a Go trial on 80% of trials and the No-Go trial on 20% of trials. On a Go trial first the subject was required to make a single poke into a specified port to receive reinforcement. On a No-Go trial, the house light flashing served as the No-Go stimulus and required the subject to not poke into any ports to receive reinforcement. Once subjects met criteria for this phase, they advanced to phase 3, which proceeded exactly as phase 2 but collected the go reaction time (GoRT), which was the latency from when the Go stimulus illuminated to when the subject performed a nosepoke into that port. Here an individually titrated LH was introduced on the Go and No-Go stimuli, which required the subject to respond to the Go stimulus, or withhold a response in the presence of the No-Go stimulus, in the LH period equal to the 90th percentile of their GoRT in order to receive reinforcement. By adding the individually titrated LH, we were able to record omissions to the Go stimulus, which was a necessary measure for calculating an index of inhibition. Subjects that met criteria for this phase advanced to the testing phase 4.

Phase 4 was the testing phase and occurred 10 months after DOX treatment. Trials presented during phase 4 are summarized in Fig. 1. The setup for this phase was the same as phase 3 with the exception that the No-Go trials were increased to 50% of the trials. During this phase, $P_{Inhibition}$ was calculated from the number of omitted Go and No-Go trials. The formula is summarized below. The product of this formula is bound between 1 and −1 where numbers closer to −1 indicate more inhibition on Go trials, numbers closer to 1 indicate more inhibition on No-Go trials, and numbers around 0 indicate a lack of discrimination between Go and No-Go trials. Test phase takes place on a single day and subjects were removed from the study once they complete their test phase.

$$P_{Inhibition} = \frac{P_{No-go} - P_{Omission}}{1 - P_{Omission}}$$

Note that P_{No-Go} indicates the proportion of correct omissions during No-Go trials to the total number of No-Go trials, whereas $P_{Omission}$ indicates the proportion of incorrect omissions during Go trials to the total number of Go trials. Values closer to 0 indicate lower omissions than values closer to 1.

In addition to the $P_{Inhibition}$, P_{No-Go}, and $P_{Omission}$ scores, perseverative and premature responses were tracked as indices of hyperactivity. A perseverative response was counted as any responses made into the Start stimulus after the initial response requirement is met. The total number of perseverative responses made on either trial type was combined and compared between subjects. A premature response was counted when the subject made a response into the Start or Go stimulus before that stimulus was illuminated. The total number of premature responses on either stimulus were combined and compared between subjects. Traditionally, premature responding has been a measure of impulsivity; however, studies interpreting this measure as impulsivity used timeouts in conjunction with a premature response. The task used here did not include timeouts, thus premature responses lacked a consequence and could not be interpreted as impulsivity. Finally, reinforcers earned and accuracy measurements on Go trials served as an index for motivation to earn reinforcers and ability to perform the basic trained operant response reliably.

Immunohistochemistry

At the conclusion of behavioral testing, Tat transgenic mice were anesthetized with isoflurane and perfused using a 4% paraformaldehyde solution. Brains were extracted and post-fixed in 4% paraformaldehyde for 6 h at 4 °C before being washed 3x for 1 h at room temperature in 1x phosphate buffer solution (PBS) and incubated for 24 h at 4 °C in a 20% sucrose solution. Brains were then encapsulated in Tissue-Tek O.C.T compound before being frozen and kept at −80 °C until sectioning. Coronal sections were cut using a Leica CM3000 cryostat (Leica, Deerfield, IL) at −21 ± 1 °C to a width of 30 μm thickness. Sections were washed, and then treated with a permeability solution [0.1% Triton 100x, 0.1% bovine serum albumin (BSA) in PBS] for 15 min. Following, tissue sections were washed again before being exposed to a blocking solution (1% normal goat serum, 0.2% BSA in PBS) for 1 h. Sections were then incubated overnight at 4 °C in primary antibodies diluted in blocking solution against MAP2ab (mouse, Millipore, MAB378; 1:1000) and the rat CB_1R-NH (raised to amino acids 1–77 of the N-terminus; rabbit; 1:500, Tsou et al. 1998). Next day, sections were washed again before being exposed to secondary antibodies conjugated to goat-anti-mouse Alexa 488 (Molecular Probes, O-6380, 1:500, green) for MAP2ab and goat-anti-rabbit Alexa 594 (Molecular Probes, A11012; 1:1000, red) for CB_1R-NH. Secondary antibodies were diluted in the blocking solution previously described and applied for 1 h at room temperature. Following secondary application, tissue sections were washed in PBS and exposed to Hoechst (Hoechst 33342; Molecular

Fig. 1 Demonstrates one of two trial arrangements of the Go/No-Go task at the testing phase that were used in this experiment. A trial begins with the Start stimulus being illuminated and the subject is required to make a response into the Start stimulus to begin the trial. On Go trials, the subject is required to wait for a 2 s inter-stimulus interval (ISI) before the Go stimulus will be presented. For both Go and No-Go arrangements, responses made into the Start stimulus during this time are counted as preservative responses and responses into the Go stimulus are counted as premature responses. Once the Go stimulus illuminates, the subject has until its individually titrated limited hold period lapses to make a response before that trial is scored as an incorrect omission. If the subject responded correctly, it receives a reward and waits for a 10 s intertrial interval (ITI) before a new trial begins. An incorrect omission yields no reward and the subject must wait for the 10 s ITI before a new trial commences. The No-Go trials proceeded very similarly, except during the 2 s ISI seen in Go trials a flashing house light is presented. After 2 s, the Go stimulus is illuminated and the house light continues to flash. The subject has until its individually titrated limited hold period lapses to make an incorrect response or the trial is counted as a correct omission. If the subject correctly omitted a response, it receives a reward before waiting for the 10 s ITI to start a new trial; otherwise, the subject simply waits for the 10 s ITI with no reward. Taken together, this setup presents a conditional discrimination in which the subject is required to alter responding depending on the status of the house light. For the other trial arrangements, the role of the house light is simply reversed where now a flashing house light indicates the subject should perform a response for reinforcement. These two arrangements are counterbalanced between groups and sexes to account for any fear inducing qualities of the flashing house light. There were no statistically significant differences between the two arrangements on any measure (all p's > .05)

Probes, H3570) for 3 min. Tissue sections were then washed and mounted on SuperFrost Plus Slides (Fisher Scientific, Pittsburgh, PA) using ProLong Gold antifade mounting media (Molecular Probes, P36930).

For imaging, eight tissue sections were chosen per animal that were representative of progression through the mPFC as per the Allen Mouse Brain Atlas (2004). Confocal immuno-fluorescent images for CB$_1$R expression were gathered by an experimenter blinded to genotype and sex using a Zeiss LSM800 T-PMT laser scanning confocal microscope (Zeiss, Thornwood, NY) fitted with a 63x oil immersion objective. Images were acquired by using identical parameters for all groups (i.e., identical objective, zoom, laser intensity, gain, offset, and scan speed) optimized for control tissues. ZEN 2010 blue edition software (Carl Zeiss, Inc., Thornwood, NY) was used to collect the images. Four images were taken

per tissue section (2 images from the left and 2 images from the right hemisphere), with unique fields of view for each section, one from the prelimbic (PL) and one from the infralimbic (IL) region of each hemisphere. The entire image was used as region of interest and processed using ImageJ (Schneider et al. 2012) to quantify the density of CB$_1$R-NH staining per pixel in each image. Mean fluorescent intensities were determined with ImageJ without digital manipulation. For each animal, in each brain region (PL and IL), data are averaged across sections.

Western Blot Analysis

Western blot analysis was carried out as previously described (Xu et al. 2017). In brief, tissue from the mPFC of Tat trans-genic mice (DOX exposure for more than 5 months) was

freshly harvested and homogenized on ice in an appropriate volume of ice-cold RIPA Lysis and Extraction buffer (G-Bioscience) with protease inhibitor cocktail (Amresco, Ohio). Blots were incubated with anti-CB$_1$R (rabbit polyclonal; Cayman; 1:1000 dilution for 3 h), and anti β-Actin (anti-mouse from Cell Signaling; 1:1000 for 3 h) at room temperature. ECL reaction (Amersham) was used to dectect immunoreactive bands from the blot using BioRad Gel Doc XR+ system and image acquiring software (Image Lab ver. 5.1). Densitometric analysis used a modified version (version 1.59) of the Scion Image software (Scion Corporation).

Electrophysiology

For the electrophysiology experiments brain slices of Tat transgenic mice (DOX exposure for at least ~1 month) were prepared following an established procedure as previously described (Xu et al. 2016). Mice were anesthetized with isofluorane and brains were removed after decapitation and submerged into ice-cold sucrose cutting solution containing in mM: 254 sucrose, 10 D-glucose, 26 NaHCO$_3$, 2 CaCl$_2$, 2 MgSO$_4$, 3 KCl, and 1.25 NaH$_2$PO$_4$, saturated with 95% O$_2$/5% CO$_2$, at pH 7.4, 300 mOsm. Coronal brain slices (300 μm thickness) containing the mPFC were obtained using the VT 1000S microtome (Leica, Deerfield, IL). Slices were then incubated at 32 ± 1 °C for 30 min in artificial cerebrospinal fluid (aCSF) and maintained at room temperature for at least an additional 30 min before start of the experiment. At the start of the experiment slices were transferred to a submersion chamber (Warner Instruments, Hamden, CT) on a Siskiyou 4080P fixed-stage system (Grants Pass, OR) with a continuous flow rate of 2–3 mL/min aCSF saturated with 95% O$_2$/5% CO$_2$ at 32 ± 1 °C using an inline heater (Warner SC-20, Hamden, CT). Slices were visualized using an Axio Examiner A1 microscope (Zeiss, Thornwood, NY) equipped with a 40x water-immersion objective coupled with an infrared differential interference contrast and an integrated Dodt gradient camera system. Recordings were taken from mPFC pyramidal neurons of layer 2/3, including the PL and IL regions, and were identified as being approximately 50–250 μm from the slice midline and possessing a pyramidal neuron morphology. Patch recording pipettes with ~5 MΩ resistance were fabricated using a PC-10 puller (Narishige, Greencale, NY). For the whole-cell patch-clamp recordings the intracellular recording solution contained in mM unless otherwise stated: 115 K-gluconate, 10 HEPES, 5 KCl, 2 MgCl$_2$, 2 Mg-ATP, 2 Na$_2$-ATP, 0.4 Na$_2$GTP and 10 Na$_2$-phosphocreatine (pH 7.33). Recordings from mPFC neurons were amplified and filtered at 2 kHz (MultiClamp 700B amplifier, Axon Instruments, Union City, CA), and digitized with a sampling rate of 10 kHz (Digidata 1550A, Axon Instruments). Spontaneous currents were recorded at resting membrane potential (~75 ± 5 mV). Therefore, inward currents are considered excitatory amino acid currents (EPSCs), whereas the outward currents (inhibitory postsynaptic currents, IPSCs) were blocked by bath application of bicuculline (10 μM). Drugs, such as PF3845 (1 μM) were administered by bath application and synaptic currents were collected for 5 min for each experimental condition. Access resistance (<25 MΩ) was regularly monitored during recordings, and cells were rejected if resistance changed >15% during the experiment. Off-line analysis of synaptic currents was performed using the Minianalysis software (Version 6.0.8; Synaptosoft, Decatur, GA). Data for PF3845 conditions are presented as PF3845-induced change (Δ) on sEPSC frequency and sEPSC amplitude, indicating percent inhibition from control (control is set to 0%). Quantitative analyses were performed on 14–26 neurons per group.

Statistical Analysis

All descriptive statistics are reported as means (M) ± standard error of the mean (SEM). All statistical analyses were conducted using one-way or two-way analysis of variances (ANOVAs) with Sex (2 levels: male, female) and/or Genotype [2 levels: Tat(−), Tat(+)] as factors, followed by Tukey's post hoc tests if necessary. An alpha level of $p < .05$ was considered significant for all statistical tests used. Additionally, for the PF3845-induced inhibition data on sEPSCs a one-sample t-test was conducted to determine whether PF3845 significantly inhibited currents from percent control. When analyzing each group separately multiple comparisons were controlled for by dividing the alpha level by the number of comparisons. The relationship between inhibitory control and CB$_1$R expression was assessed by Pearson correlation and simple linear regression analyses. Simple linear regression analysis was conducted to determine if observed changes in CB$_1$R expression was significantly predictive of the behavioral measure inhibitory control. Effect sizes are reported using ω^2 to best represent population effect size using an unbiased estimate (Yiğit and Mendes 2018).

Results

Behavioral Testing

Results from behavioral testing are summarized in Fig. 2. A two-way ANOVA revealed a significant interaction between Sex and Genotype on P$_{Inhibition}$, $F (1, 10) = 6.61$, $p = .028$, $\omega^2 = .27$ (Fig. 2a). Specifically female Tat(+) mice ($M = .06$, $SEM = .05$) demonstrated poorer inhibitory control than male Tat(+) mice ($M = .72$, $SEM = .12$; $p = .048$). There was no significant main effect of Sex or Genotype on P$_{Inhibition}$ (all p'-s > .05). When considering the results for P$_{Inhibition}$, it is important to remember that this score derives from inhibition on

Fig. 2 Details results from the Go/No-Go operant task. In all panels, data is organized, from left to right, as male Tat(−), male Tat(+), female Tat(−), and female Tat(+). **(a)** $P_{Inhibition}$ indicates the probability that a subject will correctly inhibit its behavior when signaled (No-Go trials) while remaining sensitive to incorrect omissions (Go trials) and is obtained through the formula: $P_{Inhibition} = (P_{No-Go} - P_{Omission})/(1 - P_{Omission})$. Using this calculation, $P_{Inhibition}$ provides data on inhibitory control, or the ability of the subject only to omit responses when appropriate. When $P_{Inhibition} = 1$, the subject performed perfectly and only omitted responses during the No-Go trials; when $P_{Inhibition} = 0$, the subject either did not omit any responses or omitted every response. Data demonstrate a significant Sex by Genotype interaction on inhibitory control ($^{\#}p = .028$) with female Tat(+) mice showing poorer inhibitory control compared to male Tat(+) subjects [$*p = .048$ vs. male Tat(+)]. **(b)** $P_{Omission}$ indicates the proportion of incorrect omissions during go trials to the total number of go trials. Values closer to 0 indicate lower incorrect omissions than values closer to 1. Data demonstrate that subjects in all groups show a low likelihood that they will incorrectly inhibit a nosepoke on a go trial. No significant differences

were noted between groups. **(c)** P_{No-Go} indicates the proportion of correct omissions during no-go trials to the total number of no-go trials. Values indicate the likelihood that a subject will correctly omit a response on a no-go trial with values closer to 0 indicating a lesser likelihood than values closer to 1. A significant Sex by Genotype interaction was noted on P_{No-Go} ($^{\#}p = .038$) with female Tat(+) mice showing less correct omissions on No-Go trials compared to male Tat(+) subjects. **(d)** Perseverative responses across both trial types. Perseverative responses are nosepokes into the Start stimulus after the response requirement for beginning the trial has already been met. No significant differences were noted between groups. **(e)** Premature responses across both trial types. Premature responses are responses made into the Go stimulus before the Go stimulus is presented. A significant main effect of Sex ($^{\S}p = .028$) was noted on premature responding with males making more premature responses than females. **(f)** Mean accuracy responses across all Go trials for the test session without any significant differences between groups. **(g)** Mean reinforcers earned across all Go trials for the test session without any significant differences between groups

both Go and No-Go trials and that a low score can stem from suppression of operantly trained behavior on Go trials, as recorded by $P_{Omission}$, or from a lack of inhibition on No-Go trials, as recorded by P_{No-Go}. When considering scores

for $P_{Ommision}$ no significant main effect of Sex or Genotype was noted, nor was there a significant interaction between Sex and Genotype (Fig. 2b; all p's > .05). Importantly, there was a significant interaction of Sex and Genotype on P_{No-Go}, F (1, 10) = 5.70, p = .038, ω^2 = .24 (Fig. 2c), with Tat expression inducing less inhibitory responses on No-Go trials in females in contrast to male mice. There was no significant main effect of Sex or Genotype on P_{No-Go} (all p's > .05). When considered together, this pattern of results indicates that the differences seen in $P_{Inhibition}$ scores are due to a failure of low scorers to inhibit on No-Go trials and not because of a performance deficit on Go trials. Thus we can interpret the low scorers as exhibiting poorer inhibitory control compared to high scorers.

Additionally, a two-way ANOVA examining differences in premature responses based on Sex and Genotype revealed a significant main effect of Sex on premature responses, F (1, 10) = 6.57, p = .028, ω^2 = .31 (Fig. 2e). Specifically male mice (M = 41.57, SEM = 10.58) performed more premature responses than female mice (M = 10.57, SEM = 2.85). There was no significant main effect of Genotype nor a significant interaction between Sex and Genotype of premature responses (all p's > .05). Furthermore, on perseverative responses no significant main effect was noted for Sex or Genotype, nor a significant Sex by Genotype interaction (Fig. 2d; all p's > .05).

Lastly, two variables served as diagnostics to identify if any subject failed to perform or learn the task, including reinforcers earned and accuracy. A two-way ANOVA indicated that all animals reliably performed the task with no significant effects found for Sex and/or Genotype on number of reinforcers earned (Fig. 2f; all p's > .05) or accuracy (Fig. 2g; all p's > .05). Notably each group earned >40 reinforcers and had >80% accuracy at test indicating no disruptions in trained operant behavior during test phase.

Immunohistochemistry

Results from immunohistochemistry staining examining differences in CB_1R density for the PL and IL regions of the mPFC are summarized in Fig. 3. A two-way ANOVA on the PL region revealed no significant main effect of Sex or Genotype, nor a significant interaction between Sex and Genotype (Fig. 3d; all p's > .05). In contrast, a two-way ANOVA on the IL region revealed a significant main effect for Sex, F (1, 10) = 8.55, p = .015, ω^2 = .21, as well as a significant Sex by Genotype interaction, F (1, 10) = 11.36, p = .007, ω^2 = .29. Specifically, female Tat(+) mice (M = 1.97, SEM = .04) showed greater CB_1R expression compared to any other group (Fig. 3e; female Tat(−) mice: M = 1.43, SEM = .20; p = .023; male Tat(−) mice: M = 1.48, SEM = .11; p = .026; male Tat(+) mice: M = 1.29, SEM = .01; p = .006).

Relationship between Inhibitory Control and CB_1R Expression

Results of the relationship between PFC-related behavioral inhibitory control and CB_1R expression in the PL and IL regions are summarized in Fig. 4. A Pearson correlation demonstrated no significant correlation between $P_{Inhibition}$ and CB_1R expression in the PL region (r = −.371, p = .191; Fig. 4a) but a significant negative correlation for the IL region (r = −.543, p = .045; Fig. 4b), indicating an association between inhibitory control deficits and an upregulation of CB_1R expression in the IL of the mPFC. The significant correlation between inhibitory control and CB_1R expression in the IL region was further assessed by a simple linear regression analysis using IL CB_1R expression as a predictor variable. Results indicate predictability of $P_{Inhibition}$ by CB_1R expression in the IL region accounting for 30% of total variance of inhibitory control [R^2 = .295; $F(1, 12)$ = 5.01, p = .045].

Western Blot Analysis

Results for the female Tat transgenic mice from western blot analysis for CB_1R protein expression are summarized in Fig. 5. A one-way ANOVA revealed a significant main effect of Genotype on CB_1R protein expression, F (1, 4) = 53.17, p = .002, ω^2 = .90 (Fig. 5b). Specifically, female Tat(+) mice (M = .80, SEM = .08) demonstrated a significant upregulation of CB_1R protein expression compared the female Tat(−) control mice (M = .20, SEM = .00).

Electrophysiology

Results from electrophysiology recordings are summarized in Fig. 6. A two-way ANOVA revealed a significant main effect of Genotype on sEPSC frequency, F (1, 75) = 7.38, p = .008, ω^2 = .07 (Fig. 6b). Specifically, Tat(+) mice (M = .79, SEM = .12) showed increased sEPSC frequency compared to Tat(−) mice (M = .38, SEM = .07). Additionally, a significant difference was noted between female Tat(−) mice (M = .27, SEM = .04) and male Tat(+) mice (M = .82, SEM = .13; p = .026). There was no significant main effect of Sex or Sex by Genotype interaction on sEPSC frequency (all p's > .05). No significant main effects or interaction were noted on sEPSC amplitude (all p's > .05; Fig. 6c).

For bath application of PF3845 (1 μM) a one-sample t-test demonstrated a significant inhibitory effect of PF3845 on percent sEPSC frequency, $t(83)$ = −15.27, p < .001 (Fig. 6e). Separate one-sample t-tests demonstrated PF3845-induced percent inhibition for all groups except for male Tat(−) mice [male Tat(+): $t(13)$ = −14.55, p < .001; female Tat(−): $t(27)$ = −13.33, p < .001; female Tat(+): $t(28)$ = −10.72, p < .001]. A two-way ANOVA revealed a significant main effect of Genotype on percent inhibition of sEPSC frequency by

Fig. 3 Shows the immunohistochemistry data on CB$_1$R expression. **(a)** A representative brain slice (left hemisphere) of a Tat transgenic mouse stained for Hoechst (blue) with outlining the regions of interest, the PL and IL in the mPFC. **(b)** Higher magnification images of the PL region at 20x (**b'**) and 63x (**b''**) show staining for MAP2ab (green) and endogenous CB$_1$R (red), with CB$_1$Rs being specifically localized in the soma of mPFC neurons. **(c)** Similarly, higher magnification images of the IL region at 20x (**c'**) and 63x (**c''**) show staining for MAP2ab (green) and endogenous CB$_1$R (red). **(d)** CB$_1$R expression is quantified by averaging the intensity of the CB$_1$R staining per pixel in the PL. No significant differences were noted between groups. **(e)** Quantification of CB$_1$R expression in the IL. There was a significant main effect of Sex ([§]$p = .015$) and a Sex by Genotype interaction for CB$_1$R intensity per pixel ([#]$p = .007$). Specifically, female Tat(+) animals had higher CB$_1$R intensity compared to any of the other three groups [*$p < .05$ vs. female Tat(+)]. Scale bars: 20 μm. PL: prelimbic, IL: infralimbic, mPFC: medial prefrontal cortex

PF3845, $F(1, 80) = 12.21$, $p = .001$, $\omega^2 = .12$. Specifically, Tat(+) mice ($M = -69.24$, $SEM = 4.54$) showed more inhibition by PF3845 compared to Tat(−) mice ($M = -48.18$, $SEM = 5.91$). Additionally, there was a significant interaction between Sex and Genotype on percent inhibition of sEPSC frequency, $F(1, 80) = 4.40$, $p = .039$, $\omega^2 = .04$. Specifically male Tat(−) mice ($M = -28.53$, $SEM = 15.01$) demonstrated less inhibition by PF3845 compared to male Tat(+) mice ($M = -71.67$, $SEM = 5.01$; $p = .006$) and compared to female Tat(+) mice ($M = -68.07$, $SEM = 6.35$; $p = .003$).

For PF3845-induced change on percent sEPSC amplitude, a one-sample t-tests revealed significant PF3845-induced

Fig. 4 Shows the relationship between inhibitory control assessed in the Go/No-Go task ($P_{Inhibition}$) and CB_1R expression assessed by immunohistochemistry in the mPFC. **(a)** A Pearson correlation indicates no significant correlation between $P_{Inhibition}$ and CB_1R expression in the PL region of the mPFC. **(b)** For the IL a significant negative correlation was noted between $P_{Inhibition}$ and CB_1R expression (*$r = -.543$,

$p = .045$), suggesting observed deficits in inhibitory control are associated with an upregulation in CB_1R expression in the IL. A simple linear regression model demonstrates that CB_1R expression is able to explain 30% of the total variance of inhibitory control assessed in the Go/No-Go task (*$R^2 = .295$, $p = .045$). PL: prelimbic, IL: infralimbic, mPFC: medial prefrontal cortex


Fig. 5 Shows the western blot data on CB_1R protein expression in the mPFC of female Tat transgenic mice. **(a)** Shows representative immunoblots for CB_1R and β-actin. **(b)** Quantification of CB_1R protein expression indicated a significant main effect of Genotype (*$p = .002$) with female Tat(+) animals demonstrating increased CB_1R protein levels compared to female Tat(−) controls. mPFC: medial prefrontal cortex

inhibition for female Tat(+) mice only, $t(28) = -3.11$, $p = .016$ (Fig. 6f). A two-way ANOVA revealed a significant main effect of Sex, $F(1, 80) = 4.45$, $p = .038$, $\omega^2 = .04$. Specifically, female mice ($M = -9.43$, $SEM = 3.41$) showed more inhibition by PF3845 than male mice ($M = 2.87$, $SEM = 5.24$). Additionally, there was a significant main effect of Genotype on percent inhibition of sEPSC amplitude, $F(1, 80) = 7.22$, $p = .009$, $\omega^2 = .07$. Specifically, Tat(+) mice ($M = -13.31$, $SEM = 4.25$) showed more inhibition by PF3845 compared to Tat(−) mice ($M = 2.73$, $SEM = 3.58$). There was no significant Sex by Genotype interaction on percent inhibition of sEPSC amplitude ($p > .05$). Additionally, a significant difference was noted between male Tat(−) mice ($M = 10.67$, $SEM = 9.07$) and female Tat(+) mice ($M = -17.63$, $SEM = 5.67$; $p = .006$).

Discussion

The purpose of the current study was to investigate the behavioral profiles of Tat transgenic mice in a PFC-related operant conditioning task. Specifically in the post-cART era, a sharp increase has been observed in cortical cognitive deficiencies (Hardy and Vance 2009; Scott et al. 2011) with HIV-1 patients displaying more problems in executive function, memory consolidation, and inhibitory control, thus involving the PFC (Cysique et al. 2004; Garvey et al. 2009; Heaton et al. 2011). Our main objective was to demonstrate that Tat expression would lead to observable inhibitory control deficits as a result of prolonged Tat exposure. While it does not appear that Tat expression alone can account for differences in inhibitory control, the vulnerability towards prolonged Tat exposure

Fig. 6 Details the electrophysiology data on spontaneous excitatory postsynaptic currents (sEPSCs) assessed in the mPFC in the presence and absence of PF3845 (1 μM) application. (a) Representative traces show sEPSCs on PFC brain slices for a control Tat(−) mouse and a transgenic Tat(+) subject. (b) A significant main effect of Genotype ($^{¶}p = .008$) was noted on sEPSC frequency [$*p = .026$ vs. male Tat(+)]. (c) No significant differences on sEPSC amplitude were noted between groups. (d) Representative traces show sEPSCs on mPFC brain slices of a male transgenic Tat(+) subject before and after PF3845 (1 μM) bath application. (e) A significant effect was noted when applying PF3845 (1 μM) to the bath with PF3845 significantly inhibiting percent sEPSC frequency for all groups except for male Tat(−) mice [$^{ϕ}p < .001$ vs.

control response (0%) for each of the corresponding groups]. Additionally a significant main effect of Genotype ($^{¶}p = .001$) was noted on sEPSC frequency as well as a significant Sex by Genotype interaction ($^{#}p = .039$) with male Tat(−) mice showing less inhibition by PF3845 compared to male Tat(+) mice and female Tat(+) subjects [$*p < .05$ vs. male Tat(+)]. (f) For the PF3845-induced change on sEPSC amplitude a significant effect was noted, with PF3845 significantly inhibiting percent sEPSC amplitude only for female Tat(+) mice [$^{ϕ}p = .016$ vs. control response (0%) of female Tat(+) subjects]. Further a significant main effect of Sex ($^{§}p = .038$) was noted on PF3845-induced percent inhibition as well as a significant main effect of Genotype [$^{¶}p = .009$; $*p = .006$ vs. male Tat(−)]. mPFC: medial prefrontal cortex

seems to be sex-dependent. Results from the GNG task demonstrated increased inhibitory control deficits in female Tat(+) mice on $P_{Inhibition}$ compared to their male counterparts. This

holds true despite results on premature responding that did not mirror the pattern of inhibitory control deficits demonstrated by $P_{Inhibition}$ data, but indicated a sex effect with males

emitting more premature responses compared to females. In past literature, premature responding has been referred to as a measure of impulsivity, which is best captured through use of timeouts in the experimental design to implement a negative consequence to incorrect responses (Bari et al. 2008; Finn et al. 1999; Robbins 2002). As in the current study the use of timeouts slowed acquisition of the task to a near standstill, we removed timeouts for the reported GNG task. Therefore, premature responses in our study may be better characterized as an index of hyperactivity rather than impulsivity. Hyperactivity has been shown to be more prominent in males in a disease state compared to females (Acharjee et al. 2014; van den Buuse et al. 2017). Nevertheless, future studies should attempt to fade in timeouts for various incorrect responses potentially after the task has been acquired to help Tat transgenic mice learn the task.

The inhibitory control deficits demonstrated by $P_{Inhibition}$ in our female Tat(+) mice are somewhat surprising as various past studies have reported higher vulnerability of male transgenic Tat(+) mice in different tasks, including rotarod activity and foregrip strength (Hahn et al. 2015b), and anxiety-like behaviors (Paris et al. 2014b). The lower vulnerability of females has suggested to be related to the documented neuroprotective role of classic steroid hormones estrogen (Hoffman et al. 2006; Paris et al. 2016; Tang et al. 1996) and its induced expression of anti-oxidants (Kumar et al. 2011; Rao et al. 2011). Additionally, human literature also supports the notion of male sex being a risk factor for increasing severity of HAND symptoms (Joska et al. 2011; Liu et al. 1996). Nevertheless it should be noted that studies focusing on HAND in populations exposed to resource-limited environments reported women to exhibit higher rates and intensity of symptoms compared to men (Chiesi et al. 1996; Gupta et al. 2007; Hestad et al. 2012; Wojna et al. 2006). It is suggested that an interaction between environmental stress and immune function might moderate the relationship between sex and severity of symptoms. In the current study, food restriction of our mice could potentially have served as a source of stress (Jensen et al. 2013; Yadawa and Chaturvedi 2016). Future studies may want to look at indicators of stress in the brain in an attempt to correlate levels of stress with severity of inhibitory control deficits.

The HIV-1 rodent literature is not devoid of studies that have shown female rodents to exhibit greater deficits in other domains of behavior on operant conditioning tasks. Most of these studies point to sex differences, with females showing a higher intensity of inflammatory responses in the hippocampus and therefore neuroinflammation serves as a key factor in accounting for these differences (Devi et al. 2010; Schwarz and Bilbo 2012; Zhang et al. 2008). There is a need for further research to investigate sex differences in PFC neuroinflammation, but available research points to greater expression of proinflammatory cytokines in female mice following

intermediate ethanol exposure (Pascual et al. 2017). Sex differences in neuroinflammation are the likely cause of sex differences in signal detection task performance in HIV-1 transgenic rats; a recent study demonstrated that female HIV-1 transgenic rats were slower to acquire a signal detection task and had lower accuracy at test compared to males (McLaurin et al. 2017). Furthermore, while overall response rates were much lower for female HIV-1 transgenic rats, female mice specifically had lower correct rejections, which is akin to the lower P_{No-Go} scores characterized in the current study. While the exact neural mechanisms contributing to differences in performance on this task require additional exploration, neuroinflammation is a mechanism that has been demonstrated to potentially account for observed behavioral deficits in a number of disorders including HAND (Appay and Sauce 2008; Boska et al. 2014; Sas et al. 2007). Furthermore, the contribution of Tat to neuroinflammation in the CNS to promote neuronal injury and synaptic dysfunction has been reported in multiple studies in Tat transgenic mouse models (Hahn et al. 2015b; Paris et al. 2015; Paris et al. 2016) and other preclinical in vivo rodent models, e.g. Tat injections (Marker et al. 2013; Puccini et al. 2015). Even though an enhanced state of glial activation and additional evidence of impaired neurogenesis in the striatum appears to be specifically upregulated in male Tat(+) mice compared to females (Hahn et al. 2015a; Hahn et al. 2015b) further studies need to investigate the sex-dependent effects for neuroinflammation in the PFC.

As the eCB system has attracted interest as a target for treatment of neurodegenerative disorders, such as Parkinson's disease and Alzheimer's disease (Pertwee 2014; Scotter et al. 2010), we were interested in investigating the role of the eCB system, which regulates both immune function and cognition, as a potential target for treatment of HAND. When focusing on CB_1R expression our immunohistochemistry data indicated that female Tat(+) mice who exhibited the poorest ability of inhibitory control in turn had the greatest expression of CB_1R levels in the IL mPFC. We were able to confirm this significant upregulation of CB_1R expression at the protein level by western blot analysis with female Tat(+) mice indicating significant higher CB_1R protein expression levels in the mPFC compared to their control Tat(−) counterparts. An upregulation of CB_1Rs has been reported in other experimental disease models, such as Parkinson's disease (Brotchie 2003) as well as in brain tissue of HIV-1 infected patients with encephalitis (Cosenza-Nashat et al. 2011). Our data showed a correlation between the degree of IL CB_1R upregulation and deficits on the GNG task, specifically on the ability of our subjects to perform an alternative to the Go response on No-Go trials, indicating IL machinery was disrupted in those animals with the highest levels of CB_1R expression. The IL mPFC is important for modifying previously learned associations allowing the organism to emit alternative behaviors once task parameters become ambiguous

(Mukherjee and Caroni 2018). In our study, inhibition on No-Go trials represents an alternative behavior to the Go response as the same Go stimulus is present on both trial types. In this way, disrupted functionality of this region accounts for the decreased probability a subject would emit the alternative response on a No-Go trial. Further experiments are needed to determine if the upregulation of CB_1Rs observed in female Tat(+) mice contributes to the deficits seen in the GNG task or whether this upregulation is a compensatory response to the observed Tat-induced inhibitory control deficits in this group. Upregulation of cannabinoid receptors is seen in a number of other neurodegenerative disorders, such as Parkinson's disease and Alzheimer's disease, however their role is disease progression is still unclear (Benito et al. 2003; Farkas et al. 2012; Lastres-Becker et al. 2001; Lee et al. 2010; Ramirez et al. 2005; Van Laere et al. 2009; Westlake et al. 1994). Nevertheless, even though our data support the notion of an upregulation in CB_1R expression, decreased or no change in CB_1R expression has also been reported in a disease state depending on the brain region involved (Bedse et al. 2014; Benito et al. 2005; Silverdale et al. 2001). Further, as brain inflammation is a common feature in HIV-1 infection, an upregulation of CB_2R appears to play an important role in HIV-1 encephalitis and simian immunodeficiency virus (SIV) (Benito et al. 2005; Cosenza-Nashat et al. 2011). While CB_1R is abundantly expressed in the cortex specifically on pyramidal neurons, CB_2R is expressed sparingly throughout the cortex but the greatest population exists on glial cells (Benito et al. 2008; Marsicano and Lutz 1999; Tsou et al. 1998). Quantitative image analysis of brains from HIV-1 infected patients with encephalitis indicated significant increases in CB_2R expression in microglia, astrocytes and perivascular macrophages (Cosenza-Nashat et al. 2011). Despite the conflicting literature on changes in CB_1R and CB_2R expression levels in disease, it is agreed that the eCB system is a key modulator of synaptic function and is implicated in the progression of neurodegenerative disorders.

For synaptic function, the current study was able to demonstrate a significant disruption of synaptic function in the mPFC as indicated by the increased sEPSC frequency in Tat(+) mice compared to their Tat(−) counterparts (males and females). Enhanced glutamatergic neurotransmission by Tat has been demonstrated in previous in vitro studies (Brailoiu et al. 2008; Green and Thayer 2016; Musante et al. 2010; Xu et al. 2017) and is suggested to be mediated via Tat's actions on NMDARs (Eugenin et al. 2007; Green and Thayer 2016; Raybuck et al. 2017) as well as non-NMDARs (Nath et al. 1996), leading to calcium influx, oxidative stress, and neuronal injury (Kaul et al. 2001). The Tat-induced increases in excitability, with the enhancement of the sEPSCs frequency but not affecting their amplitude has been reported recently in vitro (Xu et al. 2017) and suggests a presynaptic stimulatory effect on glutamate release (Brailoiu et al. 2008). Interestingly,

CB_1R stimulation has been demonstrated to limit glutamate-mediated synaptic excitation (Rossi et al. 2011). The involvement of the CB_1Rs located on glutamatergic terminals is critical for the neuroprotective effects of eCBs in counteracting excitotoxicity (Chiarlone et al. 2014). It is known that upon excessive glutamate release, eCBs are produced perisynaptically to engage with presynaptic CB_1Rs to inhibit excitatory transmission thus buffering against the excitotoxic effects of NMDAR activity in the postsynaptic neuron (Chiarlone et al. 2014; Huang et al. 2001). Various studies have shown that CB_1Rs mediate the neuroprotective effects that eCBs exhibit against excitotoxic damage and inflammation (Shen and Thayer 1998; Xu et al. 2017). However, even though the activation of CB_1Rs is known to be neuroprotective, therapeutic use of direct CB_1R agonist is limited due to the pervasive psychoactive side effects associated with CB_1R agonists that include sensorimotor, affective and cognitive disturbances (Di Marzo 2008). Additionally, given the speed at which eCBs are broken down, administration of eCB ligands is sure to have only a transient impact as they are immediately degraded by their corresponding eCB-metabolizing enzymes (Blankman and Cravatt 2013). Thus, neuroprotective effects can be achieved using eCB enzyme inhibitors, such as inhibiting the main AEA-metabolizing enzyme fatty acid amide hydrolase (FAAH), as demonstrated in a recent in vitro primary PFC neuron culture study in the context of Tat-toxicity (Hermes et al. 2018). Indeed, in the present study by using the FAAH enzyme inhibitor PF3845, which acts on CB_1R-related mechanisms, Tat-induced increase on sEPSCs frequency was attenuated when bath applied, with Tat(+) brain slices being affected significantly more compared to Tat(−) brain slices (male and females). These results point towards neuroprotective effects by modulating eCB enzyme activity, potentially due to upregulation of AEA levels by PF3845. Noteworthy, in the context of Tat toxicity the upregulation of eCB signaling by PF3845 has been shown to not only dependent on CB_1R-dependent mechanisms but also CB_2R involvement (Hermes et al. 2018). Additionally, FAAH enzyme inhibition can also elevate non-cannabinoid lipid mediators (e.g., palmitoylethanolamide (PEA) and oleoylethanolamide (OEA)), which produce anti-inflammatory effects through a non-CR-mediated mechanism of action (i.e., peroxisome proliferator-activated receptor alpha). Despite the finding that PF3845 involves more than just CB_1R-related mechanisms, our current study indicates the possibility for future studies to modulate the eCB system in vivo and examine the influence on Tat-induced behavioral deficits.

Conclusion

In conclusion, the results of the present study indicate that the GNG task is a viable method to assess inhibitory control deficits

associated with HAND in the Tat transgenic mouse model. Female Tat(+) animals showed greater inhibitory control deficits which is most likely due to sex differences in inflammatory responses to excitotoxic injury. These deficits are associated with an upregulation of CB_1R. Further experiments are required to determine whether the observed CB_1R upregulation is a compensatory response to Tat induced excitotoxicity or is contributing to the deficit as a part of disease pathogenesis. Tat also leads to an increase in sEPSCs, which may indicate a mechanism for how Tat eventually results in excitotoxic injury. These increases in sEPSC are attenuated by an eCB enzyme inhibitor, PF3845. Taken together, these results indicate a viable strategy to address damage precipitated by Tat may come in the form of therapies that modulate activity of the eCB system through use of enzyme inhibitors.

Compliance with Ethical Standards

Ethical Approval   All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Conflict of Interest   The authors declare that they have no conflicts of interest.

References

Acharjee S, Branton WG, Vivithanaporn P, Maingat F, Paul AM, Dickie P, Baker GB, Power C (2014) HIV-1 Nef expression in microglia disrupts dopaminergic and immune functions with associated mania-like behaviors. Brain Behav Immun 40:74–84. https://doi.org/10.1016/j.bbi.2014.02.016

Ahn K, McKinney MK, Cravatt BF (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108:1687–1707. https://doi.org/10.1021/cr0782067

Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S, Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van Becelaere K, Stevens RC, Cravatt BF (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16:411–420. https://doi.org/10.1016/j.chembiol.2009.02.013

Andre VM, Cepeda C, Cummings DM, Jocoy EL, Fisher YE, William Yang X, Levine MS (2010) Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. Eur J Neurosci 31:14–28. https://doi.org/10.1111/j.1460-9568.2009.07047.x

Appay V, Sauce D (2008) Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 214:231–241. https://doi.org/10.1002/path.2276

Bari A, Dalley JW, Robbins TW (2008) The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nat Protoc 3:759–767. https://doi.org/10.1038/nprot.2008.41

Bedse G, Romano A, Cianci S, Lavecchia AM, Lorenzo P, Elphick MR, Laferla FM, Vendemiale G, Grillo C, Altieri F, Cassano T, Gaetani S (2014) Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 40:701–712. https://doi.org/10.3233/JAD-131910

Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23:11136–11141

Benito C, Kim WK, Chavarria I, Hillard CJ, Mackie K, Tolon RM, Williams K, Romero J (2005) A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci 25:2530–2536. https://doi.org/10.1523/JNEUROSCI.3923-04.2005

Benito C, Tolon RM, Pazos MR, Nunez E, Castillo AI, Romero J (2008) Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol 153:277–285. https://doi.org/10.1038/sj.bjp.0707505

Blankman JL, Cravatt BF (2013) Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65:849–871. https://doi.org/10.1124/pr.112.006387

Booker L, Kinsey, SG, Abdullah, RA, Blankman, JL, Long, JZ, Ezzili, C, Boger, DL, Cravatt, , BF, Lichtman, AH (2012) The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol 165: 2485–2496 doi:https://doi.org/10.1111/j.1476-5381.2011.01445.x

Boska MD, Dash PK, Knibbe J, Epstein AA, Akhter SP, Fields N, High R, Makarov E, Bonasera S, Gelbard HA, Poluektova LY, Gendelman HE, Gorantla S (2014) Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Molecular Neurodegeneration 9:58. https://doi.org/10.1186/1750-1326-9-58

Brailoiu GC, Brailoiu E, Chang JK, Dun NJ (2008) Excitatory effects of human immunodeficiency virus 1 tat on cultured rat cerebral cortical neurons. Neuroscience 151:701–710. https://doi.org/10.1016/j.neuroscience.2007.11.031

Brotchie JM (2003) CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 3:54–61. https://doi.org/10.1016/s1471-4892(02)00011-5

Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Geurin T, Chauhan A, Reid R, Xu R, Nath A, Knapp PE, Hauser KF (2008) Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia 56:1414–1427. https://doi.org/10.1002/glia.20708

Carey AN, Sypek EI, Singh HD, Kaufman MJ, McLaughlin JP (2012) Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav Brain Res 229:48–56. https://doi.org/10.1016/j.bbr.2011.12.019

Chen P, Mayne M, Power C, Nath A (1997) The tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases. J Biol Chem 272:22385–22388

Cheng J, Nath A, Knudsen B, Hochman S, Geiger JD, Ma M, Magnuson DS (1998) Neuronal excitatory properties of human immunodeficiency virus type 1 tat protein. Neuroscience 82:97–106

Chevaleyre V, Takahashi KA, Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29:37–76. https://doi.org/10.1146/annurev.neuro.29.051605.112834

Chiarlone A, Bellocchio L, Blazquez C, Resel E, Soria-Gomez E, Cannich A, Ferrero JJ, Sagredo O, Benito C, Romero J, Sanchez-Prieto J, Lutz B, Fernandez-Ruiz J, Galve-Roperh I, Guzman M (2014) A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci U S A 111:8257–8262. https://doi.org/10.1073/pnas.1400988111

Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, Schwander S, Goebel FD, Glauser M, Antunes F, Lundgren JD (1996) Epidemiology of AIDS dementia complex in Europe AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 11:39–44

Connolly CG, Bischoff-Grethe A, Jordan SJ, Woods SP, Ellis RJ, Paulus MP, Grant I (2014) Altered functional response to risky choice in HIV infection. PLoS One 9:e111583. https://doi.org/10.1371/journal.pone.0111583

Cosenza-Nashat MA, Bauman A, Zhao ML, Morgello S, Suh HS, Lee SC (2011) Cannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities. Neuropathol Appl Neurobiol 37:464–483. https://doi.org/10.1111/j.1365-2990.2011.01177.x

Cysique LA, Maruff P, Brew BJ (2004) Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 10:350–357. https://doi.org/10.1080/13550280490521078

Devi L, Alldred MJ, Ginsberg SD, Ohno M (2010) Sex- and brain region-specific acceleration of beta-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Mol Brain 3:34. https://doi.org/10.1186/1756-6606-3-34

Di Marzo V (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7:438–455. https://doi.org/10.1038/nrd2553

El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, Hauser KF (2005) Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 tat. Glia 50:91–106. https://doi.org/10.1002/glia.20148

El-Hage N, Bruce-Keller AJ, Yakovleva T, Bazov I, Bakalkin G, Knapp PE, Hauser KF (2008) Morphine exacerbates HIV-1 tat-induced cytokine production in astrocytes through convergent effects on [Ca2+]i, NF-κB trafficking and transcription. PLoS One 3:e4093. https://doi.org/10.1371/journal.pone.0004093

Ellis R, Langford D, Masliah E (2007) HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 8:33–44. https://doi.org/10.1038/nrn2040

Ernst T, Chang L, Arnold S (2003) Increased glial metabolites predict increased working memory network activation in HIV brain injury. Neuroimage 19:1686–1693

Eugenin EA, King JE, Nath A, Calderon TM, Zukin RS, Bennett MV, Berman JW (2007) HIV-tat induces formation of an LRP-PSD-95-NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes proc. Natl Acad Sci U S a 104:3438–3443. https://doi.org/10.1073/pnas.0611699104

Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, Grant I, Mallory M, Masliah E (1999) Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HIV Neurobehavioral Research Center Brain Pathol 9:209–217

Farkas S, Nagy K, Palkovits M, Kovacs GG, Jia Z, Donohue S, Pike V, Halldin C, Mathe D, Harkany T, Gulyas B, Csiba L (2012) [(1)(2)(5)I]SD-7015 reveals fine modalities of CB(1) cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease. Neurochem Int 60:286–291. https://doi.org/10.1016/j.neuint.2011.11.004

Finn PR, Justus A, Mazas C, Steinmetz JE (1999) Working memory, executive processes and the effects of alcohol on go/no-go learning: testing a model of behavioral regulation and impulsivity. Psychopharmacology 146:465–472

Fitting S, Xu R, Bull C, Buch SK, El-Hage N, Nath A, Knapp PE, Hauser KF (2010) Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 177:1397–1410. https://doi.org/10.2353/ajpath.2010.090945

Fitting S, Knapp PE, Zou S, Marks WD, Bowers MS, Akbarali HI, Hauser KF (2014) Interactive HIV-1 tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na+ influx, mitochondrial instability, and Ca2+ overload. J Neurosci 34:12850–12864. https://doi.org/10.1523/JNEUROSCI.5351-13.2014

Garvey LJ, Yerrakalva D, Winston A (2009) Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy AIDS. Res Hum Retroviruses 25:765–769. https://doi.org/10.1089/aid.2008.0292

Green MV, Thayer SA (2016) NMDARs adapt to neurotoxic HIV protein tat downstream of a GluN2A-ubiquitin ligase signaling pathway. J Neurosci 36(50):12640–12649. https://doi.org/10.1523/JNEUROSCI.2980-16.2016

Green MV, Raybuck JD, Zhang X, Wu MM, Thayer SA (2018) Scaling synapses in the presence of HIV. Neurochem Res. https://doi.org/10.1007/s11064-018-2502-2

Gubner NR, Wilhelm CJ, Phillips TJ, Mitchell SH (2010) Strain differences in behavioral inhibition in a go/no-go task demonstrated using 15 inbred mouse strains alcohol. Clin Exp res 34:1353–1362. https://doi.org/10.1111/j.1530-0277.2010.01219.x

Gupta JD, Satishchandra P, Gopukumar K, Wilkie F, Waldrop-Valverde D, Ellis R, Ownby R, Subbakrishna DK, Desai A, Kamat A, Ravi V, Rao BS, Satish KS, Kumar M (2007) Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J Neurovirol 13:195–202. https://doi.org/10.1080/13550280701258407

Hahn YK, Masvekar RR, Xu R, Hauser KF, Knapp PE (2015a) Chronic HIV-1 tat and HIV reduce Rbfox3/NeuN: evidence for sex-related effects. Curr HIV res 13:10–20

Hahn YK, Podhaizer EM, Farris SP, Miles MF, Hauser KF, Knapp PE (2015b) Effects of chronic HIV-1 tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior brain. Struct Funct 220:605–623. https://doi.org/10.1007/s00429-013-0676-6

Hardy DJ, Vance DE (2009) The neuropsychology of HIV/AIDS in older adults. Neuropsychol Rev 19:263–272. https://doi.org/10.1007/s11065-009-9087-0

Harkany T, Mackie K, Doherty P (2008) Wiring and firing neuronal networks: endocannabinoids take center stage. Curr Opin Neurobiol 18:338–345. https://doi.org/10.1016/j.conb.2008.08.007

Harrison KM, Song R, Zhang X (2010) Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 53:124–130. https://doi.org/10.1097/QAI.0b013e3181b563e7

Haughey NJ, Holden CP, Nath A, Geiger JD (1999) Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium

in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. J Neurochem 73:1363–1374

Hauser KF, Hahn YK, Adjan VV, Zou S, Buch SK, Nath A, Bruce-Keller AJ, Knapp PE (2009) HIV-1 Tat and Morphine Have Interactive Effects on Oligodendrocyte Survival and Morphology. Glia 57: 194–206. https://doi.org/10.1002/glia.20746

Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, Group C, Group H (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3–16. https://doi.org/10.1007/s13365-010-0006-1

Hermes DJ, Xu C, Poklis JL, Niphakis MJ, Cravatt BF, Mackie K, Lichtman AH, Ignatowska-Jankowska BM, Fitting S (2018) Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS. Neuropharmacology 141:55–65. https://doi.org/10.1016/j.neuropharm.2018.08.013

Hestad KA, Menon JA, Silalukey-Ngoma M, Franklin DR Jr, Imasiku ML, Kalima K, Heaton RK (2012) Sex differences in neuropsychological performance as an effect of human immunodeficiency virus infection: a pilot study in Zambia, Africa. J Nerv Ment Dis 200:336–342. https://doi.org/10.1097/NMD.0b013e31824cc225

Hoffman GE, Merchenthaler I, Zup SL (2006) Neuroprotection by ovarian hormones in animal models of neurological disease. Endocrine 29:217–231. https://doi.org/10.1385/ENDO:29:2:217

Huang CC, Lo SW, Hsu KS (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532:731–748

Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, Abdullah RA, Tao Q, O' Neal ST, Walentiny DM, Wiley JL, AH CBFL (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171:1392–1407. https://doi.org/10.1111/bph.12298

Ignatowska-Jankowska B, Wilkerson, JL, Mustafa, M, Abdullah, R, Niphakis, M, Wiley, JL, Cravatt, BF, Lichtman, A. H. (2015) Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice. J Pharmacol Exp Ther 353:424–432 doi:https://doi.org/10.1124/jpet.114.222315

Jensen TL, Kiersgaard MK, Sorensen DB, Mikkelsen LF (2013) Fasting of mice: a review. Lab Anim 47(4):225–240. https://doi.org/10.1177/0023677213501659

Johnson TP, Patel K, Johnson KR, Maric D, Calabresi PA, Hasbun R, Nath A (2013) Induction of IL-17 and nonclassical T-cell activation by HIV-tat protein proc. Natl Acad Sci U S a 110:13588–13593. https://doi.org/10.1073/pnas.1308673110

Joska JA, Westgarth-Taylor J, Myer L, Hoare J, Thomas KG, Combrinck M, Paul RH, Stein DJ, Flisher AJ (2011) Characterization of HIV-Associated Neurocognitive Disorders among individuals starting antiretroviral therapy in South Africa AIDS. Behav 15:1197–1203. https://doi.org/10.1007/s10461-010-9744-6

Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410:988–994. https://doi.org/10.1038/35073667

Kesby JP, Hubbard DT, Markou A, Semenova S (2014) Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice addiction. Biology 19:593–605. https://doi.org/10.1111/adb.12023

Kesby JP, Markou A, Semenova S, Translational Methamphetamine ARCG (2015) Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice.

Eur Neuropsychopharmacol 25:141–150. https://doi.org/10.1016/j.euroneuro.2014.07.014

Kumar P, Kale RK, McLean P, Baquer NZ (2011) Protective effects of 17beta estradiol on altered age related neuronal parameters in female rat brain. Neurosci Lett 502:56–60. https://doi.org/10.1016/j.neulet.2011.07.024

Kutsch O, Oh J, Nath A, Benveniste EN (2000) Induction of the chemokines interleukin-8 and IP-10 by human immunodeficiency virus type 1 tat in astrocytes. J Virol 74:9214–9221

Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernandez-Ruiz JJ (2001) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets Eur J Neurosci 14:1827-1832

Lee JH, Agacinski G, Williams JH, Wilcock GK, Esiri MM, Francis PT, Wong PT, Chen CP, Lai MK (2010) Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex Neurochem Int 57:985-989. https://doi.org/10.1016/j.neuint.2010.10.010

Lichtman AH, Blankman JL, Cravatt BF (2010) Endocannabinoid overload. Mol Pharmacol 78:993–995. https://doi.org/10.1124/mol.110.069427

Lipton SA (1993) Human immunodeficiency virus-infected macrophages, gp120, and N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 33:227–228. https://doi.org/10.1002/ana.410330218

Liu X, Marder K, Stern Y, Dooneief G, Bell K, Todak G, Joseph M, Elsadr W, Williams JB, Ehrhardt A, Stein Z, Mayeux R (1996) Gender differences in HIV-related neurological progression in a cohort of injecting drug users followed for 3.5 years. J NeuroAIDS 1:17–30

Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, Tanzi RE, Moir RD, Nath A, He JJ (2000) Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat med 6:1380–1387. https://doi.org/10.1038/82199

Liu Q, Bhat M, Bowen WD, Cheng J (2009) Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. J Pharmacol Exp Ther 331:1062–1070. https://doi.org/10.1124/jpet.109.156216

Longordo F, Feligioni M, Chiaramonte G, Sbaffi PF, Raiteri M, Pittaluga A (2006) The human immunodeficiency virus-1 protein transactivator of transcription up-regulates N-methyl-D-aspartate receptor function by acting at metabotropic glutamate receptor 1 receptors coexisting on human and rat brain noradrenergic neurones. J Pharmacol Exp Ther 317:1097–1105. https://doi.org/10.1124/jpet.105.099630

Loos M, Staal J, Schoffelmeer ANM, Smit AB, Spijker S, Pattij T (2010) Inhibitory control and response latency differences between C57BL/6J and DBA/2J mice in a go/no-go and 5-choice serial reaction time task and strain-specific responsivity to amphetamine. Behavioural brain research 214:216–224. https://doi.org/10.1016/j.bbr.2010.05.027

Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A (1995) Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 37:373–380. https://doi.org/10.1002/ana.410370314

Marker DF, Tremblay ME, Puccini JM, Barbieri J, Gantz Marker MA, Loweth CJ, Muly EC, Lu SM, Goodfellow VS, Dewhurst S, Gelbard HA (2013) The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders. J Neurosci 33:9998–10010. https://doi.org/10.1523/JNEUROSCI.0598-13.2013

Marks WD, Paris JJ, Schier CJ, Denton MD, Fitting S, McQuiston AR, Knapp PE, Hauser KF (2016) HIV-1 tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations. J Neurovirol 22:747–762. https://doi.org/10.1007/s13365-016-0447-2

Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213–4225

Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84–88. https://doi.org/10.1126/science.1088208

Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I (1997) Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. The HIV Neurobehavioral Research Center Ann Neurol 42:963–972. https://doi.org/10.1002/ana.410420618

Mattson MP, Haughey NJ, Nath A (2005) Cell death in HIV dementia cell death differ. 12 Suppl 1:893-904. https://doi.org/10.1038/sj.cdd.4401577

Maung R, Hoefer MM, Sanchez AB, Sejbuk NE, Medders KE, Desai MK, Catalan IC, Dowling CC, de Rozieres CM, Garden GA, Russo R, Roberts AJ, Williams R, Kaul M (2014) CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120. J Immunol 193:1895–1910. https://doi.org/10.4049/jimmunol.1302915

McLaurin KA, Booze RM, Mactutus CF, Fairchild AJ (2017) Sex matters: robust sex differences in signal detection in the HIV-1 transgenic rat front. Behav Neurosci 11:212. https://doi.org/10.3389/fnbeh.2017.00212

Mediouni S, Darque A, Baillat G, Ravaux I, Dhiver C, Tissot-Dupont H, Mokhtari M, Moreau H, Tamalet C, Brunet C, Paul P, Dignat-George F, Stein A, Brouqui P, Spector SA, Campbell GR, Loret EP (2012) Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect Disord Drug Targets 12:81–86

Mediouni S, Jablonski J, Paris JJ, Clementz MA, Thenin-Houssier S, McLaughlin JP, Valente ST (2015) Didehydro-cortistatin a inhibits HIV-1 tat mediated neuroinflammation and prevents potentiation of cocaine reward in tat transgenic mice. Curr HIV res 13:64–79

Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wolfel B, Dodt HU, Zieglgansberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51:455–466. https://doi.org/10.1016/j.neuron.2006.07.006

Mukherjee A, Caroni P (2018) Infralimbic cortex is required for learning alternatives to prelimbic promoted associations through reciprocal connectivity. Nature Communications 9 doi:https://doi.org/10.1038/s41467-018-05318-x

Musante V, Summa M, Neri E, Puliti A, Godowicz TT, Severi P, Battalglia G, Raiteri M, Pittaluga A (2010) The HIV-1 viral protein tat increases glutamate and decreases GABA exocytosis from human and mouse neocortical nerve endings. Cereb Cortex 20(8):1974–1984. https://doi.org/10.1093/cercor/bhp274

Naidoo V, Nikas SP, Karanian DA, Hwang J, Zhao J, Wood JT, Alapafuja SO, Vadivel SK, Butler D, Makriyannis A, Bahr BA (2011) A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity. J Mol Neurosci 43:493–502. https://doi.org/10.1007/s12031-010-9472-4

Nath A (2002) Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J infect dis 186(Suppl 2):S193–S198. https://doi.org/10.1086/344528

Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N, Geiger JD (1996) Identification of a human immunodeficiency virus type 1 tat epitope that is neuroexcitatory and neurotoxic. J Virol 70:1475–1480

Niphakis MJ, Cognetta AB 3rd, Chang JW, Buczynski MW, Parsons LH, Byrne F, Burston JJ, Chapman V, Cravatt BF (2013) Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors ACS. Chem Neurosci 4:1322–1332. https://doi.org/10.1021/cn400116z

Paris JJ, Carey AN, Shay CF, Gomes SM, He JJ, McLaughlin JP (2014a) Effects of conditional central expression of HIV-1 tat protein to potentiate cocaine-mediated psychostimulation and reward among male mice. Neuropsychopharmacology 39:380–388. https://doi.org/10.1038/npp.2013.201

Paris JJ, Fenwick J, McLaughlin JP (2014b) Progesterone protects normative anxiety-like responding among ovariectomized female mice that conditionally express the HIV-1 regulatory protein, Tat, in the CNS. Hormones and behavior 65:445–453. https://doi.org/10.1016/j.yhbeh.2014.04.001

Paris JJ, Singh HD, Ganno ML, Jackson P, McLaughlin JP (2014c) Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat. Psychopharmacology (Berl) 231:2349–2360. https://doi.org/10.1007/s00213-013-3385-1

Paris JJ, Singh HD, Carey AN, McLaughlin JP (2015) Exposure to HIV-1 tat in brain impairs sensorimotor gating and activates microglia in limbic and extralimbic brain regions of male mice. Behav brain res 291:209–218. https://doi.org/10.1016/j.bbr.2015.05.021

Paris JJ, Zou S, Hahn YK, Knapp PE, Hauser KF (2016) 5alpha-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 tat brain, behavior, and immunity. https://doi.org/10.1016/j.bbi.2016.01.007

Parker LA, Niphakis MJ, Downey R, Limebeer CL, Rock EM, Sticht MA, Morris H, Abdullah RA, Lichtman AH, Cravatt BF (2015) Effect of selective inhibition of monoacylglycerol lipase (MAGL) on acute nausea, anticipatory nausea, and vomiting in rats and Suncus murinus. Psychopharmacology (Berl) 232:583–593. https://doi.org/10.1007/s00213-014-3696-x

Pascual M, Montesinos J, Marcos M, Torres JL, Costa-Alba P, Garcia-Garcia F, Laso FJ, Guerri C (2017) Gender differences in the inflammatory cytokine and chemokine profiles induced by binge ethanol drinking in adolescence. Addict Biol 22:1829–1841. https://doi.org/10.1111/adb.12461

Pertwee RG (2014) Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications proc. Nutr Soc 73:96–105. https://doi.org/10.1017/S0029665113003649

Petrosino S, Di Marzo V (2010) FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11:51–62

Puccini JM, Marker DF, Fitzgerald T, Barbieri J, Kim CS, Miller-Rhodes P, Lu SM, Dewhurst S, Gelbard HA (2015) Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders. J Neurosci 35:5271–5283. https://doi.org/10.1523/JNEUROSCI.0650-14.2015

Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25:1904–1913. https://doi.org/10.1523/JNEUROSCI.4540-04.2005

Rao AK, Dietrich AK, Ziegler YS, Nardulli AM (2011) 17beta-estradiol-mediated increase in cu/Zn superoxide dismutase expression in the brain: a mechanism to protect neurons from ischemia the journal of

steroid biochemistry and molecular. Biology 127:382–389. https://doi.org/10.1016/j.jsbmb.2011.06.008

Raybuck JD, Hargus NJ, Thayer SA (2017) A GluN2B-selective NMDAR antagonist reverses synapse loss and cognitive impairment produced by the HIV-1 protein tat. J Neurosci 37:7837–7847. https://doi.org/10.1523/JNEUROSCI.0226-17.2017

Robbins TW (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 163:362–380. https://doi.org/10.1007/s00213-002-1154-7

Rossi S, Furlan R, De Chiara V, Muzio L, Musella A, Motta C, Studer V, Cavasinni F, Bernardi G, Martino G, Cravatt BF, Lutz B, Maccarone M, Centonze D (2011) Cannabinoid CB1 receptors regulate neuronal TNF-alpha effects in experimental autoimmune encephalomyelitis brain. Behav Immun 25:1242–1248. https://doi.org/10.1016/j.bbi.2011.03.017

Sas AR, Bimonte-Nelson HA, Tyor WR (2007) Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. AIDS 21:2151–2159. https://doi.org/10.1097/QAD.0b013e3282f08c2f

Schneider CA, Rasband WS, Eliceiri KW (2012) NIH image to ImageJ: 25 years of image analysis. Nat Methods 9:671–675

Schwarz JM, Bilbo SD (2012) Sex, glia, and development: interactions in health and disease. Horm Behav 62:243–253. https://doi.org/10.1016/j.yhbeh.2012.02.018

Scott JC, Woods SP, Carey CL, Weber E, Bondi MW, Grant I, Group HIVNRC (2011) Neurocognitive consequences of HIV infection in older adults: an evaluation of the "cortical" hypothesis. AIDS Behav 15:1187–1196. https://doi.org/10.1007/s10461-010-9815-8

Scotter EL, Abood ME, Glass M (2010) The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 160:480–498. https://doi.org/10.1111/j.1476-5381.2010.00735.x

Shen M, Thayer SA (1998) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 54:459–462

Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM (2001) Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 169:400–406. https://doi.org/10.1006/exnr.2001.7649

Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348:429–432. https://doi.org/10.1016/S0140-6736(96)03356-9

Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L (1994) Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367:188–193. https://doi.org/10.1038/367188a0

Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393–411

Van den Buuse M, Low JK, Kwek P, Martin S, Gogos A (2017) Selective enhancement of NMDA receptor-mediated locomotor hyperactivity by male sex hormones in mice. Psychopharmacology (Berl) 234:2727–2735. https://doi.org/10.1007/s00213-017-4668-8

Van Laere K, Goffin K, Bormans G, Casteels C, Mortelmans L, de Hoon J, Grachev I, Vandenbulcke M, Pieters G (2009) Relationship of type 1 cannabinoid receptor availability in the human brain to novelty-seeking temperament. Arch Gen Psychiatry 66:196–204. https://doi.org/10.1001/archgenpsychiatry.2008.530

Wang YQ, Pan Y, Zhu S, Wang YG, Shen ZH, Wang K (2017) Selective impairments of alerting and executive control in HIV-infected patients: evidence from attention network test. Behav Brain Funct 13:11. https://doi.org/10.1186/s12993-017-0129-0

Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63:637–652

Wojna V, Skolasky RL, Hechavarria R, Mayo R, Selnes O, McArthur JC, Melendez LM, Maldonado E, Zorrilla CD, Garcia H, Kraiselburd E, Nath a (2006) Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol 12:356–364 doi: https://doi.org/10.1080/13550280600964576

Xu C, Hermes DJ, Mackie K, Lichtman AH, Ignatowska-Jankowska BM, Fitting S (2016) Cannabinoids occlude the HIV-1 tat-induced decrease in GABAergic neurotransmission in prefrontal cortex slices. J Neuroimmune Pharmacol. https://doi.org/10.1007/s11481-016-9664-y

Xu C, Hermes DJ, Nwanguma B, Jacobs IR, Mackie K, Mukhopadhyay S, Lichtman AH, Ignatowska-Jankowska B, Fitting S (2017) Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 tat protein. Mol cell Neurosci 83:92–102. https://doi.org/10.1016/j.mcn.2017.07.003

Yadawa AK, Chaturvedi CM (2016) Expression of stress hormones AVP and CRH in the hypothalamus of Mus musculus following water and food deprivation. Gen Comp Endocrinol 239:13–20. https://doi.org/10.1016/j.ygcen.2016.03.005

Yiğit S, Mendes M (2018) Which effect size measure is appropriate for one-way and two-way ANOVA models? A Monte Carlo Simulation Study vol 16

Zhang XM, Zhu SW, Duan RS, Mohammed AH, Winblad B, Zhu J (2008) Gender differences in susceptibility to kainic acid-induced neurodegeneration in aged C57BL/6 mice. Neurotoxicology 29:406–412. https://doi.org/10.1016/j.neuro.2008.01.006